CVS Health (CVS) Leerink Global Healthcare Conference 2026 summary
Event summary combining transcript, slides, and related documents.
Leerink Global Healthcare Conference 2026 summary
9 Mar, 2026Strategic vision and integration
Leadership is focused on integrating pharmacy, PBM, and healthcare delivery assets to create a differentiated consumer experience across 9,000 community pharmacies and primary care locations.
Recent acquisitions and partnerships, such as Oak Street, Signify, and Cordavis, are leveraged to drive affordability and access, including launching biosimilars with significant cost savings.
Technology investments have improved store operations, consumer-facing applications, and enabled seamless prescription transfers and benefit visibility.
Expansion of pharmacists' roles and capacity is a priority, aiming to provide more non-acute and non-chronic care solutions.
The enterprise strategy emphasizes connecting assets to enhance consumer convenience and drive better healthcare outcomes.
Regulatory and market adaptation
Recent PBM legislation aligns with the transparent TrueCost model, which offers drug-level specific pricing and is being phased in ahead of regulatory deadlines (late 2028–early 2029).
The transition to new PBM models is expected to maintain durable margins, with mid-teens CAGR targeted through 2028.
The organization is actively managing rebate guarantee pressures and recontracting processes, with $500 million in headwinds spread through 2026.
Adjustments to drug pricing models, such as TrueCost, are designed to neutralize list price volatility and focus on net costs.
Strong selling season for 2026 with over $6 billion in net new revenue and high client retention (>98%).
Pharmacy and reimbursement evolution
CostVantage was implemented to address reimbursement erosion, shifting to a transparent, fixed-margin per script model for predictability and stability.
The pharmacy footprint has been optimized to 9,000 locations, with opportunistic expansion through Rite Aid file acquisitions.
The pharmacy of the future is envisioned as a hub for more clinical care, integrated digital experiences, and standardized service delivery.
Competitive landscape now includes national chains, independents, grocery stores, and disruptive innovators, with a focus on leveraging technology and scale.
CostVantage aims for stable, equitable reimbursement rather than margin expansion.
Latest events from CVS Health
- 2025 revenue and EPS exceeded expectations, but earnings hit by goodwill and litigation charges.CVS
Q4 202510 Feb 2026 - Mid-teens EPS CAGR targeted through 2028, with raised guidance and AI-native platform launch.CVS
Investor Day 20253 Feb 2026 - Q2 revenue up 2.6% to $91.2B, but EPS and guidance cut amid Health Care Benefits headwinds.CVS
Q2 20242 Feb 2026 - Revenue up 6.3% to $95.4B, but large charges drove sharp earnings decline.CVS
Q3 202416 Jan 2026 - Leadership and pricing innovations set the stage for cautious but improving financial outlooks.CVS
Wolfe Research 2024 Healthcare Conference13 Jan 2026 - 2025 guidance targets EPS growth and revenue above $385B despite ongoing cost headwinds.CVS
Q4 20248 Jan 2026 - Q1 2025 revenue up 7% to $94.6B; adjusted EPS guidance raised to $6.00–$6.20.CVS
Q1 202520 Dec 2025 - 2024 saw robust financials, leadership transitions, and enhanced pay-for-performance alignment.CVS
Proxy Filing1 Dec 2025 - Key votes include board elections, auditor ratification, say-on-pay, and a shareholder rights proposal.CVS
Proxy Filing1 Dec 2025